
GRDN Stock Forecast & Price Target
GRDN Analyst Ratings
Bulls say
Guardian Pharmacy Service is viewed favorably because it has built a durable moat in a fragmented LTC pharmacy market, holding 13% national share after 20 years of execution and serving ~205,000 residents across ~8,400 facilities in 38 states. Its differentiated, technology-enabled model and value-added services support strong customer retention, while demographic tailwinds from baby boomers aging into assisted living should sustain HSD organic growth alongside a three-pronged expansion strategy. The outlook is further strengthened by accretive M&A opportunities tied to IRA-driven disruption and peer distress, plus robust financial flexibility with ~$90M of cash, no debt, and 39% ROIC over the last 12 months.
Bears say
Guardian Pharmacy Service is facing a structurally weaker earnings backdrop as the IRA compresses margins by limiting reimbursement to MFP plus a dispensing fee, which remains below typical acquisition cost even after manufacturer true-ups. The company also remains exposed to regulatory and reimbursement risk, including Medicare and Medicaid changes, PBM contract pressure, and LTC pharmacy disruption highlighted by Omnicare’s 2025 bankruptcy after a $900M+ False Claims Act judgment. Although LTC demand is supported by residents needing ADL assistance, Guardian’s reliance on pharmaceutical and medical product sales, plus risks in staffing, supply chain, and integration, limits margin resilience and upside.
This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.
GRDN Analyst Forecast & Price Prediction
Start investing in GRDN
Order type
Buy in
Order amount
Est. shares
0 shares